Aptamer Group PLC
07 October 2026
7 October 2026
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Notice of Results
Analyst Briefing and Investor Presentation
Aptamer Group plc (AIM: APTA), the developer of next-generation synthetic Optimer® binders, will announce its full year results for the year ended 30 June 2026 on Tuesday, 13 October 2026 and hold the following analyst briefing and investor presentation.
Analyst briefing
An online briefing for analysts will be hosted by Dr Arron Tolley, Chief Executive Officer and Andrew Rapson, Chief Financial Officer,at 9.30 am on Tuesday, 13 October 2026, to review the full year results. Analysts wishing to attend should contact Sarah Hollins at Northstar Communications at sarah@northstarcommunications.co.uk.
Investor presentation
An investor presentation to cover the full year results will be held at 2.00 pm on Tuesday, 13 October 2026.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet Aptamer Group plc via:
https://www.investormeetcompany.com/aptamer-group-plc/register-investor
Investors who already follow Aptamer Group plc on the Investor Meet Company platform will automatically be invited.
- Ends -
For further information, please contact:
|
Aptamer Group plc Dr Arron Tolley, Chief Executive Officer |
+44 (0) 1904 217 404 |
|
SPARK Advisory Partners Limited - Nominated Adviser Andrew Emmott / Dillon Wall |
+44 (0) 20 3368 3550 |
|
Cavendish Capital Markets Limited – Joint Broker Geoff Nash / Seamus Fricker / Joe Smith |
+44 (0) 20 7220 0500 |
|
Turner Pope Investments (TPI) Limited – Joint Broker Andrew Thacker /Guy McDougall |
+44 (0) 20 3657 0050 |
|
Northstar CommunicationsLimited - Investor Relations Sarah Hollins |
+44 (0) 113 730 3896 |
About Aptamer Group
Aptamer Group plc (AIM: APTA) develops Optimer® binders, next-generation synthetic alternatives to antibodies that offer high specificity, improved stability, lower cost and access to targets beyond the reach of conventional modalities.
The Group operates a dual-revenue model, generating near-term revenues through fee-for-service discovery programmes while building a portfolio of proprietary therapeutic assets designed to create long-term value through licensing, royalties and supply agreements.
Aptamer is strategically focused on two of the most significant challenges in modern drug development: targeting "undruggable" proteins and enabling delivery of therapeutics to tissues beyond the liver. Its proprietary Optimer® platform, supported by more than 15 years of discovery data and an expanding AI-enabled discovery engine, is designed to accelerate the identification of high-quality binders against challenging biological targets.
The Group's internal pipeline includes targeted delivery vehicles for oligonucleotide therapeutics and radioligand therapy programmes, with upcoming in vivo studies expected to support future partnering and licensing opportunities.
Founded in 2008 and headquartered in York, UK, Aptamer works with many of the world's leading pharmaceutical companies, combining platform expertise, proprietary data and therapeutic innovation to create shareholder value.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.